Nanjing King-Friend Biochemical Pharmaceutical (603707) Fundamentals 2026 — P/E 21.4x, Revenue Analysis | SniperIQ
Nanjing King-Friend Biochemical Pharmaceutical (603707) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥12.7B, trading at ¥7.87 on the SHH. This SniperIQ fundamentals page covers Nanjing King-Friend Biochemical Pharmaceutical's valuation (P/E 21.4x, P/B 1.8x), profitability (net margin 14.5%), revenue (¥4.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Nanjing King-Friend Biochemical Pharmaceutical's market cap?
Nanjing King-Friend Biochemical Pharmaceutical (603707) has a market capitalization of approximately ¥12.7B, trading at ¥7.87 on the SHH. Market cap moves with the live share price.
What is Nanjing King-Friend Biochemical Pharmaceutical's P/E ratio?
Nanjing King-Friend Biochemical Pharmaceutical's trailing twelve-month P/E ratio is 21.4x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Nanjing King-Friend Biochemical Pharmaceutical?
Nanjing King-Friend Biochemical Pharmaceutical runs a net profit margin of 14.5%, a gross margin of 39.5%, and an operating margin of 17.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Nanjing King-Friend Biochemical Pharmaceutical generate?
Nanjing King-Friend Biochemical Pharmaceutical reported revenue of ¥4.0B for fiscal year 2025, with net income of ¥582M and earnings per share (EPS) of 0.36. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Nanjing King-Friend Biochemical Pharmaceutical pay a dividend?
Nanjing King-Friend Biochemical Pharmaceutical offers a trailing dividend yield of about 1.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Nanjing King-Friend Biochemical Pharmaceutical financially healthy?
Nanjing King-Friend Biochemical Pharmaceutical carries a debt-to-equity ratio of 0.38x and a current ratio of 2.27x, with a market beta of 0.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Nanjing King-Friend Biochemical Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Nanjing King-Friend Biochemical Pharmaceutical (603707) the key facts are: market cap ¥12.7B, P/E 21.4x, revenue ¥4.0B, 52-week range 6.72-12.27. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Nanjing King-Friend Biochemical Pharmaceutical's full fundamentals live
Get Nanjing King-Friend Biochemical Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.